

6/29/07

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/828,795
	Filing Date	April 21, 2004
	First Named Inventor	Weber, Eckard
	Art Unit	1614
SHEET 1 OF 1		Examiner Kwon, Brian Yong S.
		Attorney Docket No. OREX.001A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.K./	1	6,387,956	05-14-2002	Shapira	
	2	2003-0055038	03-20-2003	Howard	
	3	2003-0130322	07-10-2003	Howard	
	4	2004-0158194	08-12-2004	Wolff, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	5	WO 94/20100	09-15-1994	Nagle et al.		
	6	WO 03/097046 A1	11-27-2003	Duke University		
	7	WO 2004/024096 A2	03-25-2004	Elan pharma		
	8	WO 2004/100992 A2	11-25-2004	Pfizer		
	9	WO 2004/050020 A2	06-17-2004	Simon, David L.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	10	Croft et al., "Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks," Clinical Therapeutics 24(4):662-672 (Apr. 2002)	
	11	McDougle, et al., "A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder," Archive of General Psychiatry, 57(8):794-801 August 2000	
	12	Nash et al., "Anxiety disorders," Medicine, 32(7):17-21, July 1, 2004	
	13	Stein, "Neurobiology of the obsessive-compulsive spectrum disorders," Biological Psychiatry 47(4):296-304 February 15, 2000	
✓	14	Stein, "Obsessive-compulsive disorder," Lancet 360(9330):397-405 August 3, 2002	

3945377
062907

Examiner Signature	/Brian-Yong Kwon/	Date Considered	11/27/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

10/19/07


PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/828795
	Filing Date	April 21, 2004
	First Named Inventor	WEBER, Eckard et al.
	Art Unit	1614
Examiner		KWON, Brian Yong S.
SHEET 1 OF 2		Attorney Docket No. OREX.001A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<div style="border: 1px solid black; border-radius: 50%; width: 20px; height: 20px; text-align: center; line-height: 20px;">11</div>	1	5403595	04-04-1995	KITCHELL, et al.	
	2	6048322	04-11-2000	KUSHIDA	<i>duplicate</i>
	3	6071918	06-06-2000	COOK	
	4	6210716	02-27-2001	SHERMAN	
	5	2002-0090615	07-11-2002	ROSEN, et al.	
	6	2002/0198227	12-26-2002	BERNSTEIN	
	7	2006-0122127	08-08-2006	RAO, et al.	
	8	2007-0117827	05-24-2007	TOLLEFSON, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
<div style="border: 1px solid black; border-radius: 50%; width: 20px; height: 20px; text-align: center; line-height: 20px;">11</div>	9	WO 03/097048 A1	11-27-2003	GADDE, et al.	<i>duplicate</i>	
	10	WO 2006/017504	02-16-2006	WEBER, et al.		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹
<div>↓</div>	11	ANDERSON, et al. Bupropion SR enhances weight loss" Obesity R., Vol. 10, N. 7, 2002, pp. 633-641, XP002351373		<i>duplicate</i>
	12	ASTRUP et al., "Thermogenic Synergism Between Ephedrine and Caffeine in Healthy Volunteers: A Double-Blind, Placebo-Controlled Study", Metabolism, March 1991, 323-329, Vol 40 (3)		
	13	ATKINSON et al., "Effects of long-term therapy with naltrexone on body weight in obesity", Clinical Pharmacology & Therapeutics, Oct 1985, 419-422, Vol. 38		<i>duplicate</i>
	14	Erfuth, et al. "Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients", Neuropsychobiology, vol. 45, no. Supplement 1, March 2002, pages 33-36		
	15	GREENWAY et al., "Double-Blind, Randomized, Placebo-Controlled Clinical Trials with Non-prescription Medications for the Treatment of Obesity", Obesity Research, July 1999, 370-78, Vol.7(4)		
	16	GREENWAY et al., "A Long-acting Leptin Analog does not Enhance Fat, Visceral Fat, or Weight Loss When Combined with Caffeine and Ephedrine in Obese Subjects", International Journal of Obesity, 2002, S136		
	17	GREIST, et al., "Double-blind Parallel Comparison of Three Dosages of Sertraline and Placebo in Outpatients With Obsessive-compulsive Disorder". Arch Gen Psychiatry. April 1995 52: 289-295		

Examiner Signature 	Date Considered 11/27/07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/828795
	Filing Date	April 21, 2004
	First Named Inventor	WEBER, Eckard et al.
	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	KWON, Brian Yong S.
SHEET 2 OF 2	Attorney Docket No.	OREX.001A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	18	JAIN, et al. "Bupropin SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms", Obesity Research, Oct 2002, 1049-56, Vol. 10	
	19	KIPTOO, et al. "Enhancement of Transdermal delivery of 6-B naltrexol via a codrug linked to hydroxybupropion, Journal of Controlled Release 113 (2006) 137-145 Duplicate	
	20	Kushner, et al. "Obesity pharmacology: past, present, and future.", Current Opinion in Gastroenterology, March 2002, pages 213-220	
	21	MALCOLM et al., "A Controlled Trial of Naltrexone in Obese Humans", International Journal of Obesity, June 1985, 347-353, Vol. 9	
	22	MITCHELL et al., "High-Dose Naltrexone Therapy and Dietary Counseling for Obesity", Biological Psychiatry, 1987, 35-42, Vol. 22	
	23	Penn, et al., "Pharmacotherapy of obesity in the near term.", Current Opinion in Endocrinology and Diabetes 2003 United States, 2003, pages 311-316	
	24	RÉNÉRIC, J. P. et al., "Opioid Receptor Antagonists in Psychiatry", CNS Drugs, Nov 1998, 10 (5): 365-377	
	25	STEIN, "Obsessive Compulsive Disorder," The Lancet, Aug 2002, 360: 397-405 Duplicate	
	26	Wadden et al. "Effects of Sibutramine Plus Orlistat in Obese Women Following 1 Year of Treatment by Sibutramine Alone: A Placebo-Controlled Trial," Obesity Research, 8(6):431 (2000) Duplicate	
	27	WEINTRAUB et al., "Long-term Weight Control Study I (weeks 0 to 34) 'The Enhancement of Behavior Modification, Caloric Restriction, and Exercise by Fenfluramine Plus Phentermine versus Placebo'", Clinical Pharmacology & Therapeutics, 1992, 586-94, Vol 51(5)	

4431720
101807

Examiner Signature	Date Considered 11/27/07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.